3 employees
iFAST is addressing the Antimicrobial Susceptibility Testing market, reducing the spread of antimicrobial resistance.
2022
$2.4M
from 1 investors over 1 rounds
iFAST Diagnostics raised $2.4M on January 1, 2023
Investors: Kadmos Capital Ltd